Sutro Biopharma Inc. (STRO) Financial Statements (2025 and earlier)

Company Profile

Business Address 111 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments316,895375,618334,364197,938368,137117,864
Cash and cash equivalent190,30469,26847,25430,414206,1524,960
Short-term investments126,591306,350287,110167,524161,985112,904
Receivables8,61636,0787,12212,4545,5597,348
Other undisclosed current assets17,7999,84611,6678,1234,4863,356
Total current assets:343,310421,542353,153218,515378,182128,568
Noncurrent Assets
Operating lease, right-of-use asset17,67722,81526,44329,041  
Property, plant and equipment18,19021,94024,62122,55012,9359,633
Long-term investments and receivables    68,775 15,609
Long-term investments    68,775 15,609
Restricted cash and investments85887287287287215
Other noncurrent assets7,1723,5671,8551,6552,1222,545
Total noncurrent assets:43,89749,19453,791122,89315,92927,802
TOTAL ASSETS:387,207470,736406,944341,408394,111156,370
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities23,38024,12617,93922,74414,36711,601
Accounts payable10,4759,4404,79711,3275,5445,584
Accrued liabilities12,90514,68613,14211,4178,8236,017
Deferred revenue69,78320,66616,7595,49614,60319,465
Debt  4,06112,5009,375 1,000
Other liabilities4,0093,8973,0803,084627901
Other undisclosed current liabilities34,72140,99616,2691,037  
Total current liabilities:131,89393,74666,54741,73629,59732,967
Noncurrent Liabilities
Long-term debt and lease obligation   3,77146,96224,5458,876
Long-term debt, excluding current maturities   3,77115,73824,5458,876
Liabilities, other than long-term debt29,90478,227119,5781467,92116,738
Deferred revenue12,53653,37989,885 6,10016,195
Deferred rent credit     1,340409
Other liabilities1,6941,694119146481134
Operating lease, liability15,67423,15429,57431,224  
Other undisclosed noncurrent liabilities180,809149,114    
Total noncurrent liabilities:210,713227,341123,34947,10832,46625,614
Total liabilities:342,606321,087189,89688,84462,06358,581
Equity
Equity, attributable to parent44,601149,649217,048252,564332,04897,789
Common stock836158464623
Additional paid in capital831,348708,975670,223586,243559,746293,346
Accumulated other comprehensive income (loss)3921(618)(314)129165
Accumulated deficit(786,869)(559,408)(452,615)(333,411)(227,873)(195,745)
Total equity:44,601149,649217,048252,564332,04897,789
TOTAL LIABILITIES AND EQUITY:387,207470,736406,944341,408394,111156,370

Income Statement (P&L) ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues62,043153,73167,77261,88042,72242,736
Revenue from related parties  2,81322,536
Gain on disposition of assets for financial service operations 32,139 4,074   
Gross profit:62,043153,73167,77261,88042,72242,736
Operating expenses(300,496)(243,009)(196,715)(160,404)(113,779)(98,204)
Operating loss:(238,453)(89,278)(128,943)(98,524)(71,057)(55,468)
Nonoperating income
(Investment Income, Nonoperating)
18,64314,5103,4555771,5084,074
Interest and debt expense  (1,300)(2,400)(2,600)(2,300)(1,100)
Loss from continuing operations before equity method investments, income taxes:(219,810)(76,068)(127,888)(100,547)(71,849)(52,494)
Other undisclosed income (loss) from continuing operations before income taxes(5,288)(12,533)11,184   
Loss from continuing operations before income taxes:(225,098)(88,601)(116,704)(100,547)(71,849)(52,494)
Income tax expense(2,363)(18,192)(2,500) (100) 
Loss from continuing operations:(227,461)(106,793)(119,204)(100,547)(71,949)(52,494)
Loss before gain (loss) on sale of properties:(100,547)(71,949)(52,494)
Other undisclosed net income (loss)   (4,991)39,821(3,250)
Net loss available to common stockholders, diluted:(227,461)(106,793)(119,204)(105,538)(32,128)(55,744)

Comprehensive Income ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(227,461)(106,793)(119,204)(105,538)(32,128)(55,744)
Comprehensive loss:(227,461)(106,793)(119,204)(105,538)(32,128)(55,744)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent18639(304)(443)(36)212
Comprehensive loss, net of tax, attributable to parent:(227,443)(106,154)(119,508)(105,981)(32,164)(55,532)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: